GeoVax Labs, Inc.
No SEC Form 4 filings for $GOVX in the last 30 days.
See all $GOVX insider activity →GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held a special meeting of stockholders on October 27, 2026. The Company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares of common stock as of the record date of August 28
GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Enters into $1 Million Revolving Loan Agreement ATLANTA, GA – October 26, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has en
GeoVax Labs (GOVX) secured a $1M unsecured revolving loan at 12% interest, maturing in 12 months. The lender has discretion over advances. Five directors resigned, and three lender-nominated directors joined the board. The company faces ongoing capital needs and Nasdaq compliance risks.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning GOVX (GeoVax Labs, Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 2 bearish.
Recent GOVX coverage spans corporate actions, technology and market movers.
The approved reverse split could reduce share count and increase price per share, while the warrant exercise may dilute existing shareholders.
The financing adds modest debt and may raise concerns about dilution, while new board members could influence strategy.
The financing provides short‑term liquidity but signals ongoing cash constraints for the clinical‑stage biotech.
The announcement may lift sentiment on GeoVax as investors anticipate a near‑term data readout, but the modest scale of the trial and limited market exposure temper upside.
The construct is an early-stage development milestone; no immediate commercial impact but may boost R&D pipeline perception.
AlphAI scores every news story that mentions GOVX with an AI model for sentiment and relevance, and aggregates insider trades from GeoVax Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held a special meeting of stockholders on October 27, 2026. The Company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares of common stock as of the record date of August 28
1 min readGeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Enters into $1 Million Revolving Loan Agreement ATLANTA, GA – October 26, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has en
2 min readGeoVax Labs (GOVX) secured a $1M unsecured revolving loan at 12% interest, maturing in 12 months. The lender has discretion over advances. Five directors resigned, and three lender-nominated directors joined the board. The company faces ongoing capital needs and Nasdaq compliance risks.
1 min readGeoVax Labs (GOVX) highlighted CDC reports of sustained Clade Ib mpox transmission in the U.S. The company is advancing its GEO-MVA vaccine, aiming to start a Phase 3 trial in Q4 2026 with results expected in mid-2027. GeoVax believes its vaccine could diversify supply and enhance preparedness.
3 min readGeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD
2 min readGeoVax Labs (GOVX) supports a new global mpox vaccine stockpile initiative, funded by Gavi and WHO. The stockpile aims to provide equitable access to vaccines during outbreaks. GeoVax's CEO highlights the need for durable procurement and sufficient supply. The company's GEO-MVA vaccine candidate is advancing toward a Phase 3 study in 2026, with key milestones already achieved. GeoVax seeks to contribute to global supply resilience.
2 min readGeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Announces a Warrant Inducement Transaction ATLANTA, GA – August 26, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an e
2 min readGeoVax Labs (GOVX) announced a warrant inducement transaction with an institutional investor. The investor will exercise existing warrants to purchase up to 5.7 million shares at $0.64 per share, generating approximately $3.65 million in proceeds. In return, the investor will receive new warrants for up to 11.4 million shares. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on August 27, 2026, subject to customary
1 min readGeoVax Labs (GOVX) selected a CRO and European clinical sites for its Phase 3 study of GEO-MVA, a vaccine against mpox and smallpox. The study, planned for Q4 2026, will enroll 500 healthy adults and compare GEO-MVA's immunogenicity and safety to a licensed MVA vaccine. GeoVax aims to announce results by mid-2027, with the study's success potentially supporting EMA approval.
2 min readWerewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.
2 min read
